Company: NDRA
Filing Date: 2025-10-30
Form Type: 8-K
Source: 0001213900-25-103707
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01

Financial Statements and Exhibits.

  (d)      Exhibits  

  Exhibit No.      Description                                                                                                                             
          1.1      At-The-Market Issuance Sales Agreement by and between ENDRA Life Sciences Inc. and Lucid Capital Markets, LLC, dated October 29, 2025.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          5.1      Opinion of K& L Gates LLP.                                                                                                              
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                             

SIGNATURE

Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                        ENDRA Life Sciences Inc.                               
  October 30, 2025      By:                           /s/ Richard Jacroux      
                        Name:                         Richard Jacroux          
                        Title:                        Chief Financial Officer